Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cysteamine in preparing medicine for treating cancer

A technology of cysteamine and chemotherapeutic drugs, applied in the application field of cysteamine in the preparation of drugs for treating cancer, can solve problems such as cardiac conduction disorder, peripheral neuritis, treatment interruption, cardiotoxicity, etc. Effects with low side effects and biological toxicity

Inactive Publication Date: 2010-08-11
UNIV OF SCI & TECH OF CHINA
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, severe side effects and drug resistance of cancer cells often lead to treatment interruption or failure
Now commonly used chemotherapeutic drugs and corresponding side effects are: the side effects of cyclophosphamide (CTX) are myelosuppression and hemorrhagic cystitis; the side effects of ifosfamide (IFO) are hemorrhagic cystitis and myelosuppression; Renal toxicity, gastrointestinal reactions, ototoxicity, neurotoxicity; side effects of carboplatin (CARBO) are myelosuppression; side effects of mitoxantrone (Mx) are cardiotoxicity, bone marrow suppression; side effects of methotrexate (MT) are nephrotoxicity, Pulmonary fibrosis, oral ulcers; side effect of cytarabine (Ara-C) is liver damage; side effect of bleomycin (BLM) is pulmonary fibrosis; side effect of pingyangmycin (PYM) pulmonary fibrosis; side effect of paclitaxel (TAXOL) allergy , heart conduction disorder, peripheral neuritis; vincristine (VCR) peripheral neuritis, extravasation skin damage; 5-fluorouracil (5-FU) side effect is diarrhea; podophyllin (etoposide, VP-16) side effect is bone marrow Inhibition; the side effect of Hemeixin (TOPO) is bone marrow suppression; the side effect of Adriamycin (ADR) is cardiotoxicity, bone marrow suppression, gastrointestinal and renal toxicity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cysteamine in preparing medicine for treating cancer
  • Application of cysteamine in preparing medicine for treating cancer
  • Application of cysteamine in preparing medicine for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1. Cysteamine can induce autophagy in HeLA cancer cells [Induce autophagy in human cervical cancer HeLa cells stably expressing LC3-eGFP, and use the autophagy promoter rapmycin as a positive control]

[0036] experimental method:

[0037] 1. The method for screening human cervical cancer cells stably expressing LC3-eGFP (LC3-eGFP / HeLa) is as follows:

[0038] (1) Human cervical cancer cell HeLa cells (purchased from Shanghai Institute of Cells, Chinese Academy of Sciences) were inoculated in 24-well cell culture plates (GIBCO, USA) with DMEM medium at a density of about 3-5×10 4 / well, at 37°C, 5% (volume percent) CO 2 Incubate overnight in an incubator until use.

[0039](2) Lipofectamine2000, 1.5 μl per well, was dissolved in 100 μl of serum-free and antibiotic-free DMEM medium, mixed well and incubated at room temperature for 5 min, and the plasmid LC3-eGFP (Invitrogen Company, USA) was 2 μg per well, dissolved in 100 μl of serum-free DMEM In the antibiot...

Embodiment 2

[0046] Example 2: Cysteamine induces autophagy in 293A cells [Induces autophagy in human embryonic kidney cells 293A stably expressing LC3-eGFP, using the autophagy promoter rapmycin as a positive control]

[0047] experimental method:

[0048] 1. The method for screening human embryonic kidney cells stably expressing LC3-eGFP (LC3-eGFP / 293A) is as follows:

[0049] (1) 293A human embryonic kidney cells (purchased from Shanghai Institute of Cells, Chinese Academy of Sciences) were inoculated in 24-well cell culture plates (GIBCO, USA) with DMEM medium at a density of about 3-5×10 4 / well, at 37°C, 5% (volume percent) CO 2 Incubate overnight in an incubator until use.

[0050] (2) Prepare the transfection complex, the method is as follows: 1.5 μl of Lipofectamine2000 per well, dissolved in 100 μl of DMEM (serum-free and antibiotic-free) medium, mixed well and incubated at room temperature for 5 minutes, 2 μg of LC3-eGFP per well, dissolved in 100 μl In DMEM (serum-free and a...

Embodiment 5

[0060] Example 5: Dose effect of cysteamine on autophagy in HeLa cells [transformation of endogenous protein LC3I to autophagy marker protein LC3II]

[0061] experimental method:

[0062] 1. HeLa cells were inoculated in DMEM medium (GIBCO, USA) 24-well cell culture plate, and the cell density of the 24-well plate was about 3-5×10 4 / well, at 37°C, 5% (volume percent) CO 2 Incubate overnight in an incubator until use.

[0063] 2. Add cysteamine with a final concentration of 0.5mM, 1.0mM, 1.5mM or 2.0mM to each well, and the cells without any treatment are the control group ( Figure 5 In the control), the final concentration of the autophagy promoter was 200nM rapamycin treatment (Sigma, USA) as a positive control for causing autophagy ( Figure 5 Rapamycin in), at 37°C, 5% (volume percentage) CO 2 In an incubator, the cells were collected after 24 hours of cell culture, and the cells were lysed with a cell lysate (purchased from Beyuntian Company), and then electrophoresi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of cysteamine in preparing a medicine for treating cancer. Sensitivity on cancer cells by chemotherapeutics is increased by the cysteamine with low dosage, thereby realizing that cancer cells are effectively killed by the chemotherapeutics with low dosage. The invention greatly improves the medicine effect of the chemotherapeutics and lowers the side effects of chemotherapy.

Description

technical field [0001] The invention relates to the application of cysteamine in the preparation of medicines for treating cancer. Background technique [0002] Chemotherapy is a very effective and commonly used method for clinical treatment of cancer. However, severe side effects and drug resistance of cancer cells often lead to treatment interruption or failure. Now commonly used chemotherapeutic drugs and corresponding side effects are: the side effects of cyclophosphamide (CTX) are myelosuppression and hemorrhagic cystitis; the side effects of ifosfamide (IFO) are hemorrhagic cystitis and myelosuppression; Renal toxicity, gastrointestinal reactions, ototoxicity, neurotoxicity; side effects of carboplatin (CARBO) are myelosuppression; side effects of mitoxantrone (Mx) are cardiotoxicity, bone marrow suppression; side effects of methotrexate (MT) are nephrotoxicity, Pulmonary fibrosis, oral ulcers; side effect of cytarabine (Ara-C) is liver damage; side effect of bleomyc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/145A61P35/00
Inventor 万小妹张力温龙平
Owner UNIV OF SCI & TECH OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com